EUVIMEDEUVIMED entdecken
Crossref

Distinguishing True Immune Tolerant Hepatitis B Patients: Insights From Long‐Term Clinical Outcomes

Jung Hyun Kwon iD, Sung Won Lee, Hee-Yeon Kim iD, Do Seon Song iD, Soon Kyu Lee, Heechul Nam, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang iD

Journal of Viral Hepatitis · 2025

DOI: 10.1111/jvh.70083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Jung Hyun Kwon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Immune Tolerance. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT) & Future Planning Korea Bio Grand Challenge Prog…, National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT), Korean Association for the Study of the Liver (KASL).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The long‐term prognosis of immune tolerant (IT) phase patients remains unclear. This study aimed to identify true IT‐phase patients with favourable outcomes and distinguish grey‐zone IT patients. We retrospectively analysed 1064 chronic hepatitis B (CHB) patients (516 clinically inclusive IT, 548 antiviral‐treated immune active [AVT‐IA]). Clinically inclusive IT‐phase was defined as HBeAg‐positive, no cirrhosis, HBV DNA ≥ 10^6 IU/mL, and ALT < 80 U/L. Favourable prognosis was defined as the absence of HCC development and IA progression during follow‐up. IT‐phase patients had significantly lower 10‐year HCC rates compared to AVT‐IA patients (1.7% vs. 2.7%). Among the clinically inclusive IT group, favourable prognosis was associated with younger age (< 35 years), female gender, stringent low ALT (< 35 U/L for males, < 25 U/L for females), high HBV DNA (> 10^8 IU/mL), and no family history of HCC. Patients meeting these criteria showed no HCC cases and had a lower likelihood of progression to IA (~50%) within 10 years. The strict criteria demonstrated 90.3% specificity for identifying true IT‐phase patients within the clinically inclusive IT group. Family history of HCC was an independent risk factor for HCC development (HR 6.059, p = 0.019), while stringent low ALT, younger age, and female gender were linked to lower IA progression risk (HR 0.32, p ≤ 0.001). This study highlights the importance of applying strict criteria in distinguishing true IT‐phase patients from grey‐zone patients. True IT patients are at minimal risk of HCC or progression to IA, while identifying grey‐zone patients is crucial, as they may require early antiviral therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicImmune ToleranceHumansMaleFemaleAdultMiddle AgedRetrospective StudiesPrognosisAntiviral AgentsDNA, ViralCarcinoma, HepatocellularHepatitis B e AntigensYoung AdultTreatment OutcomeDisease ProgressionLiver NeoplasmsAgedAlanine TransaminaseHepatitis B virus

Stichwörter der Autor:innen

hepatitis Bhepatocellular carcinomaimmune tolerancenatural history

Substanzen

Antiviral AgentsDNA, ViralHepatitis B e AntigensAlanine Transaminase

Autor:innen und Institutionen

  • Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Incheon, Republic of Korea.
  • Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Bucheon, Republic of Korea.
  • Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, the Catholic University of Korea, Suwon, Republic of Korea.
  • Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Uijeongbu, Republic of Korea.
  • Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea.

ORCID-Profile: Jung Hyun Kwon, Hee-Yeon Kim, Do Seon Song, Jeong Won Jang

Förderung

  • National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT) & Future Planning Korea Bio Grand Challenge Prog…
  • National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science and ICT)
  • Korean Association for the Study of the Liver (KASL)
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Kwon, J. H., Lee, S. W., Kim, H. Y., Song, D. S., Lee, S. K., Nam, H., Nam, S. W., Bae, S. H., Choi, J. Y., Yoon, S. K., & Jang, J. W. (2025). Distinguishing True Immune Tolerant Hepatitis B Patients: Insights From Long‐Term Clinical Outcomes. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70083

Vancouver

Kwon JH, Lee SW, Kim HY, Song DS, Lee SK, Nam H, et al. Distinguishing True Immune Tolerant Hepatitis B Patients: Insights From Long‐Term Clinical Outcomes. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.70083

BibTeX
@article{Kwon2025,
  author = {Kwon, Jung Hyun and Lee, Sung Won and Kim, Hee-Yeon and Song, Do Seon and Lee, Soon Kyu and Nam, Heechul and Nam, Soon Woo and Bae, Si Hyun and Choi, Jong Young and Yoon, Seung Kew and Jang, Jeong Won},
  title = {Distinguishing True Immune Tolerant Hepatitis B Patients: Insights From Long‐Term Clinical Outcomes},
  journal = {Journal of Viral Hepatitis},
  year = {2025},
  doi = {10.1111/jvh.70083}
}
Kostenlos starten →